Long-term therapy with long-acting octreotide (Sandostatin-LAR®) for the management of acromegaly

OBJECTIVES To evaluate the efficacy and safety of a long‐acting preparation of the somatostatin analogue octreotide, Sandostatin‐LAR® (SMS‐LAR) for the treatment of acromegaly. DESIGN AND PATIENTS Thirteen patients with acromegaly received intramuscular injections of SMS‐LAR 20–40 mg at 4–6‐week int...

Full description

Saved in:
Bibliographic Details
Published in:Clinical endocrinology (Oxford) 1998-03, Vol.48 (3), p.311-316
Main Authors: Davies, Peter H., Stewart, Susan E., Lancranjan, Ioana, Sheppard, Michael C., Stewart, Paul M.
Format: Article
Language:English
Subjects:
Acromegaly - blood
Acromegaly - diagnosis
Acromegaly - drug therapy
Adult
Aged
Biological and medical sciences
Delayed-Action Preparations
Female
Gallbladder - diagnostic imaging
Gallbladder - drug effects
Growth Hormone - blood
Hormones - therapeutic use
Hormones. Endocrine system
Humans
Injections, Intramuscular
Injections, Subcutaneous
Insulin-Like Growth Factor I - analysis
Male
Medical sciences
Microspheres
Middle Aged
Octreotide - therapeutic use
Pharmacology. Drug treatments
Pituitary Gland - pathology
Somatostatin - analogs & derivatives
Ultrasonography
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:OBJECTIVES To evaluate the efficacy and safety of a long‐acting preparation of the somatostatin analogue octreotide, Sandostatin‐LAR® (SMS‐LAR) for the treatment of acromegaly. DESIGN AND PATIENTS Thirteen patients with acromegaly received intramuscular injections of SMS‐LAR 20–40 mg at 4–6‐week intervals for a period of up to 3 years. MEASUREMENTS Serial measurement of serum GH and IGF‐1 concentrations were obtained. Symptoms related to acromegaly were scored by patients at baseline and following each injection. Serial gallbladder ultrasound and pituitary imaging was performed throughout the study. RESULTS One patient was withdrawn from the study after 6 months because of continued gastrointestinal side effects; 4 patients were treated with monthly injections for 12 months and 8 patients with injections at either 1 month or 6‐week intervals for 36 months; hence data is presented for n = 12 for up to 12 months and thereafter n = 8. SMS‐LAR significantly reduced serum GH and IGF‐1 values: for the whole group GH concentrations fell from 24.8 ± 4.2 mU/l (mean ± SE) at baseline to 5.2 ± 0.8 mU/l at 12 months (P 
ISSN:0300-0664
1365-2265
DOI:10.1046/j.1365-2265.1998.00389.x